A phase 2b study of merimepodib in combination with pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] and ribavirin in subjects with chronic hepatitis C non-responsive to prior therapy with pegylated interferon alfa and ribavirin

Trial Profile

A phase 2b study of merimepodib in combination with pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] and ribavirin in subjects with chronic hepatitis C non-responsive to prior therapy with pegylated interferon alfa and ribavirin

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2009

At a glance

  • Drugs Merimepodib; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms METRO
  • Most Recent Events

    • 20 Dec 2007 Status changed from in progress to complete.
    • 24 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top